25 October 2024 : Clinical Research
Type 2 Diabetes Subtypes and Their Role in Metabolic Liver Disease and Fibrosis Progression
Froylan David Martínez-Sánchez![ORCID logo](https://jours.isi-science.com/images/id_icon_32.png)
![ORCID logo](https://jours.isi-science.com/images/id_icon_32.png)
![ORCID logo](https://jours.isi-science.com/images/id_icon_32.png)
![ORCID logo](https://jours.isi-science.com/images/id_icon_32.png)
![ORCID logo](https://jours.isi-science.com/images/id_icon_32.png)
DOI: 10.12659/MSM.946016
Med Sci Monit 2024; 30:e946016
![](https://jours.isi-science.com/imageXml.php?i=medscimonit-30-e946016-g001.jpg&idArt=946016&w=1000')
Figure 1 Type 2 diabetes subgroups distribution according to liver fibrosis stages using the Fibrosis-4 indexP value: chi-square test. MOD – mild obesity-related diabetes; MARD – mild age-related diabetes; SIDD – severe insulin-deficient diabetes; SIRD – severe insulin-resistant diabetes.